Regaining HR and fork protection by inactivation of 53BP1, RIF1, REV7, or a Shieldin, and PTIP, respectively, results in resistance to PARPi in BRCA1-deficient cancer cells [70–79]. This evidence concerns the gene MAD2L2 and cancer.